Clinical trial NCT00983073: Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic
Official title: An Evaluation of the Effectiveness and Tolerability of Tapentadol Hydrochloride Prolonged Release, and Tapentadol Hydrochloride Immediate Release on Demand, in Subjects With Uncontrolled Severe Chronic Pain Due to Osteoarthritis of the Knee Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Pain
Osteoarthritis
Keywords: Osteoarthritis
Pain
Assessment
Tapentadol
Centrally acting analgesic
Chronic pain due to osteoarthritis
Lead sponsor: Grünenthal GmbH
Sponsor class: INDUSTRY
First posted: 2009-09-23
Enrollment: 224
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking either WHO Step I or Step II analgesics or no regular analgesics. This is a clinical effectiveness trial designed to establish a link between anticipated clinical outcomes and the clinical practice by means of selected measures of clinical and subject-reported outcome.

The trial will compare the effectiveness of previous analgesic treatment (either WHO Step I or Step II analgesics or no regular analgesics) with that of tapentadol hydrochloride prolonged release (PR) treatment during defined periods of evaluation.


Eligibility criteria: Inclusion Criteria:

1. Participants have signed an Informed Consent Form indicating that they understand the purpose of and the procedures required for the trial and are willing to participate in it.
2. Participants are men or non-pregnant, non-lactating women. Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Women of childbearing potential must have a negative pregnancy test at screening.
3. Participants must be appropriately communicative to verbalize and to differentiate with regard to location and intensity of the pain.
4. Participants must be at least 40 years of age.
5. Participants must have a diagnosis of osteoarthritis of the knee based on the American College of Rheumatology (ACR) classification criteria:

   * Knee pain and
   * Radiographic osteophytes or
   * Knee pain and
   * Aged 40 years or above, and
   * Morning stiffness of less than 30 minutes of duration and
   * Crepitus on motion.
6. Participants must have pain at the reference joint which has been present for at least 3 months.
7. Participant's pain must require a strong analgesic (defined as WHO Step III) as judged by the Investigator.
8. Participants must report a rate of satisfaction with their previous analgesic regimen not exceeding "fair" on a participant satisfaction with treatment scale (5-point VRS).
9. If under regular, daily pretreatment:

   * Participants must be taking a WHO Step I or Step II analgesic medication for osteoarthritis of the knee on a daily basis for at least 2 weeks prior to the Screening Visit.
   * The Investigator considers dose increase of WHO Step I analgesics (as mono- or combination therapy) and/or continuation with or dose increase of WHO Step II analgesics inadequate for the individual participant, whatever applicable.
   * Participants must have an average pain intensity score (NRS 3) greater than 5 points during the last 3 days prior to the Screening Visit.

OR if no regular analgesic pretreatment is reported:

* Participants must have an average pain intensity score (NRS-3)greater than 6 points in the last 3 days prior to the Screening Visit and related to osteoarthritis.

Exclusion Criteria:

1. Presence of a clinically significant disease or laboratory findings that in the Investigator's opinion may affect efficacy or safety assessments.
2. Presence of active systemic or local infection, that may, in the opinion of the Investigator, affect the efficacy, quality of life/function or safety assessments.
3. History of alcohol or drug abuse, or suspicion thereof in the Investigator's judgment.
4. Presence of concomitant autoimmune inflammatory conditions.
5. Known history of or laboratory values reflecting severe renal impairment.
6. Known history of moderately or severely impaired hepatic function.
7. History of or active hepatitis B or C within the past 3 months or history of HIV infection.
8. History of seizure disorder or epilepsy.
9. Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within 15 years (consisting of 1 or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post-traumatic amnesia lasting more than 24 h) or residual sequelae suggesting transient changes in consciousness.
10. Pregnant or breast-feeding.
11. History of allergy to, or hypersensitivity to tapentadol hydrochloride or its excipients, or contraindications related to tapentadol hydrochloride including:

    * Participants with acute or severe bronchial asthma or hypercapnia.
    * Participants who have or are suspected of having paralytic ileus.
12. Employees of the Investigator or trial site, with direct involvement in this trial or other trials under the direction of the Investigator or trial site, as well as family members of employees of the Investigator.
13. Participation in another trial concurrently or within 4 weeks prior to the Screening Visit.
14. Known to or suspected of not being able to comply with the protocol and the use of the investigational medicinal product.
15. Use of monoamine oxidase inhibitors within 14 days before the Screening Visit.
16. Non-stable dosing of selective serotonin reuptake inhibitors within 30 days before the Screening Visit (Doses must remain stable during the trial).
17. Osteoarthritis in a flare state.
18. Use of intra-articular injections of hyaluronic acid in the reference joint within 3 months before the Screening Visit.
19. Presence of conditions other than osteoarthritis of the reference joint that could confound the assessment or self-evaluation of pain, e.g., anatomical deformities, significant skin conditions such as abscess or syndromes with widespread pain such as fibromyalgia. Participants with osteoarthritis at joints other than the reference joint will not be excluded as long as the reference joint is the source of main pain and disability.
20. History and clinical signs at the reference joint of crystal-induced (e.g., gout, pseudo-gout), metabolic, infectious and autoimmune disease.
21. Any concomitant painful condition that could interfere with the participants' trial assessments or with their ability to differentiate the current joint pain from other painful conditions.
22. Any painful procedures during the trial (e.g., major surgery, including the reference joint) that may, in the opinion of the Investigator, affect the efficacy or safety assessments.
23. Pending litigation due to chronic pain or disability.
24. Intake of Step III analgesics within the 30 days prior to the Screening Visit.

Primary outcomes:
measure: The Primary Endpoint is Defined as the Change From Week -1 of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6.
timeFrame: Baseline to end of week 6
Secondary outcomes:
measure: Average Pain Intensity Before the Start of Tapentadol Treatment
timeFrame: Baseline
measure: Change in Average Pain Intensity After 6 Weeks of Tapentadol PR Treatment
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Change in Average Pain Intensity After 12 Weeks of Tapentadol PR Treatment
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: EuroQol-5 (EQ-5D) Health Status Index Outcome Over Time
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Change in Health Related Quality of Life: EuroQol-5D Health State Visual Analog Scale (VAS)
timeFrame: Baseline, End of Week 12 (12 Weeks)
measure: Patient Global Impression of Change
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Patient Global Impression of Change
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: Clinical Global Impression of Change
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Clinical Global Impression of Change
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: Participant's Satisfaction With Previous Analgesic Treatment
timeFrame: Baseline
measure: Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol.
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Participant's Satisfaction With New Analgesic Treatment, i.e Tapentadol.
timeFrame: Baseline; End of Week 12 (12 Weeks)
measure: Baseline Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee
timeFrame: Baseline
measure: Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 6
timeFrame: Baseline; End of Week 6 (6 Weeks)
measure: Change From Baseline in the Western Ontario McMaster Questionnaire (WOMAC) Global Score Assessing Pain, Disability and Joint Stiffness of the Knee Over the Last Week at Week 12
timeFrame: Baseline; End of Week 12 (12 Weeks)
Other outcomes:
Locations:
city: Belfort
country: France
facility: Site 1
city: Marseille
country: France
facility: Site 4
city: Murs Erigné
country: France
facility: Site 2
city: Nantes
country: France
facility: Site 3
city: Berlin
country: Germany
facility: Site 5
city: Köln Dünnwald
country: Germany
facility: Site 2
city: Leipzig
country: Germany
facility: Site 4
city: Leipzig
country: Germany
facility: Site 6
city: Marl
country: Germany
facility: Site 1
city: Meine
country: Germany
facility: Site 3
city: Rudolstadt
country: Germany
facility: Site 8
city: Lodz
country: Poland
facility: Site 4
city: Warsawa
country: Poland
facility: Site 2
city: A Coruna
country: Spain
facility: Site 2
city: A Coruna
country: Spain
facility: Site 7
city: Lugo
country: Spain
facility: Site 6
city: Madrid
country: Spain
facility: Site 3
city: Torrelavega
country: Spain
facility: Site 1
city: London
country: United Kingdom
facility: Site 3
city: London
country: United Kingdom
facility: Site 9
city: Manchester
country: United Kingdom
facility: Site 06
city: Portsmouth
country: United Kingdom
facility: Site 08
city: Solihull
country: United Kingdom
facility: Site 1
city: Swansea
country: United Kingdom
facility: Site 4
Study officials:
affiliation: Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria Santander, Spain
name: Jaime Calvo, Dr. MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Steigerwald I, Muller M, Kujawa J, Balblanc JC, Calvo-Alen J. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study. J Pain Res. 2012;5:121-38. doi: 10.2147/JPR.S30540. Epub 2012 Jun 15.